Skip to content
value.today

PrimeGen Biotech LLC

Total raised
$22 M
4 rounds on record
Latest round
$2 M
Dec 2015
First round on record
Aug 2014
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of PrimeGen Biotech LLC
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2015$2 MNo. 4Under $2 million

PrimeGen Biotech LLC: Raise no. 4, Dec 2015

Investors in this round

1 investor had bought by the notice of May 12, 2016: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Class B Preferred Units
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • Thomas C.K. Yuen · Executive Officer, Director · Manager and Chief Executive Officer
  • Lenard Sun Makowka · Director
  • Steven D. Gershick · Director · Manager
  • Wai Sun Szeto · Director · Manager

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas C.K. Yuen, Manager. Source: SEC Form D, newest notice filed May 12, 2016. Read the notice at the SEC.

equitySEC
Oct 2015$1 MNo. 3Under $2 million

PrimeGen Biotech LLC: Raise no. 3, Oct 2015

Investors in this round

1 investor had bought by the notice of Jan 25, 2016: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Class B Preferred Units
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • Thomas C.K. Yuen · Executive Officer, Director · Manager and Chief Executive Officer
  • Steven D. Gershick · Director · Manager
  • Wai Sun Szeto · Director · Manager

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas C.K. Yuen, Manager. Source: SEC Form D, newest notice filed Jan 25, 2016. Read the notice at the SEC.

equitySEC
Apr 2015$1 MNo. 2Under $2 million

PrimeGen Biotech LLC: Raise no. 2, Apr 2015

Investors in this round

1 investor had bought by the notice of Jul 22, 2015: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Class B Preferred Units
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • Thomas C.K. Yuen · Executive Officer, Director · Manager and Chief Executive Officer
  • Steven D. Gershick · Director · Manager
  • Wai D. Szeto · Director · Manager

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas C.K. Yuen, Manager. Source: SEC Form D, newest notice filed Jul 22, 2015. Read the notice at the SEC.

equitySEC
Aug 2014$18 MNo. 1$10 to $50 million

PrimeGen Biotech LLC: Raise no. 1, Aug 2014

Investors in this round

2 investors had bought by the notice of Aug 22, 2014: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$18 M of $18 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • Thomas C.K. Yuen · Executive Officer, Director · Manager and Chief Executive Officer
  • Steven C.K. Gershick · Director · Manager
  • Wai C.K. Szeto · Director · Manager

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas C.K. Yuen, Manager. Source: SEC Form D, newest notice filed Aug 22, 2014. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • PrimeGen Biotech LLC chose not to state its revenue in its newest notice of a funding round (May 2016).

    SEC Form D · May 2016

  • The industry group it chose in its notices: Other.

    SEC Form D · May 2016

That is all the official record says: PrimeGen Biotech LLC has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of PrimeGen Biotech LLC is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 2 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by PrimeGen Biotech LLC
NameRoleNamed in
Thomas C.K. YuenManager and Chief Executive OfficerMay 2016
Lenard Sun MakowkaDirectorMay 2016
Steven D. GershickManagerMay 2016
Thomas C.K. YuenManager and Chief Executive OfficerMay 2016
Wai Sun SzetoManagerMay 2016
Wai D. SzetoManagerJul 2015
Steven C.K. GershickManagerAug 2014
Wai C.K. SzetoManagerAug 2014